A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) when Given Alone and Together with a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

Trial Identifier: 217848
Sponsor: GlaxoSmithKline
Start Date: April 2024
Primary Completion Date: November 2024
Study Completion Date: March 2025
Condition: Respiratory Syncytial Virus Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Belgium Antwerpen, Belgium, 2000
Belgium Edegem, Belgium, 2650
Belgium Gent, Belgium, 9000
Belgium Kluisbergen, Belgium, 9690
Belgium Mechelen, Belgium, 2800
Netherlands BREDA, Netherlands, 4818 CK
Netherlands ENSCHEDE, Netherlands, 7512 KZ
Netherlands UTRECHT, Netherlands, 3584 BA
Netherlands ZUTPHEN, Netherlands, 7207 AE
Spain Barcelona, Spain, 08023
Spain Barcelona, Spain, 08907
Spain Boadilla del Monte Madrid, Spain, 28660
Spain La CoruNa, Spain, 15006
Spain Madrid, Spain, 28040
Spain Madrid, Spain, 28222
Spain Madrid, Spain, 28041
United States, FL Coral Gables, FL, United States, 33134
United States, GA Savannah, GA, United States, 31406
United States, IN Evansville, IN, United States, 47714
United States, NC Winston-Salem, NC, United States, 27103
United States, NE Omaha, NE, United States, 68134
United States, NY Rochester, NY, United States, 14609
United States, SC North Charleston, SC, United States, 29405
United States, VA Newport News, VA, United States, 23606